{"_id": "64ffe61d748b29c10bbbeafb", "and": [{"age": {"$gte": 18, "$lte": 79}}, {"diagnosis": "locoregionally recurrent or second primary HNSCC in a previously radiated field"}, {"surgery": {"$lt": 56}}, {"$and": [{"margins": {"$in": ["positive", "high grade dysplasia"]}}, {"ENE": {"$exists": true}}]}, {"PD-L1 CPS": {"$gte": 1}}, {"prior radiation": {"$gt": 50}}, {"completed prior radiation": {"$gte": 180}}, {"evidence of distant disease": false}, {"anti-PD-1/PD-L1 therapy": false}, {"ECOG performance status": {"$in": [0, 1]}}, {"$or": [{"able to consent": true}, {"$and": [{"IDMC": true}, {"LAR or caregiver available": true}]}]}, {"$not": {"$or": [{"pregnant": true}, {"breast-feeding": true}, {"$and": [{"blood test or urine study": {"$lt": 14}}, {"$or": [{"urine or serum pregnancy test": {"$lt": 72}}, {"serum pregnancy test": true}]}, {"$or": [{"patient of childbearing potential": true}, {"achieved menarche": true}, {"hysterectomy or bilateral oophorectomy": false}, {"naturally postmenopausal": {"$gte": 720}}]}]}, {"expect to conceive or father children": false}]}}, {"ANC": {"$gte": 1500}}, {"platelets": {"$gte": 100000}}, {"total bilirubin": {"$lte": 1.5}}, {"AST/ALT": {"$lte": 3.0}}, {"creatinine clearance": {"$gt": 30}}, {"current active infection": false}, {"non-infectious pneumonitis": {"$lt": 3}}, {"history of transplant": false}, {"$not": {"$and": [{"immunosuppressive medication": {"$lt": 7}}, {"$or": [{"steroids": {"$in": ["intranasal", "inhaled", "topical", "local"]}}, {"systemic corticosteroids": {"$lte": 10}}, {"steroids as premedication": true}]}]}}, {"cardiac function": {"$exists": true}}, {"live vaccine": {"$lt": 30}}, {"severe hypersensitivity": {"$lt": 4}}, {"$not": {"$or": [{"active autoimmune disease": {"$lt": 2}}, {"replacement therapy": true}]}}, {"psychiatric or substance abuse disorder": false}, {"HIV-infected patients": true}, {"$not": {"$or": [{"hepatitis B": true}, {"hepatitis C virus": true}]}}], "nctId": "NCT04671667", "title": "A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features"}